Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Announces Agreement to be Acquired by Biogen Inc.
Summary
Apellis Pharmaceuticals, Inc. has entered into an Agreement and Plan of Merger with Biogen Inc. and Aspen Purchaser Sub, Inc., a wholly owned subsidiary of Biogen. Under the terms of the agreement, Biogen will acquire all outstanding shares of Apellis for $41.00 per share in cash, plus one contingent value right per share, which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash upon the achievement of certain specified milestones. The merger is expected to be completed in the second quarter of 2026, subject to certain conditions, including regulatory approvals and stockholder approval. The merger agreement also includes a tender and support agreement with certain stockholders of Apellis, who have agreed to tender their shares and vote in favor of the merger. The transaction is expected to provide significant benefits to Apellis stockholders, including a substantial premium over the current market price.
Profitelligence Alerts
Get alerts for APLS
Be first to know when Apellis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Official SEC Documents
Advertisement